Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer -April 01, 2024 at 08:06 am EDT

First of its kind study in muscle-invasive urothelial cancer, with both escalation and de-escalation arms


Approximately 1,000 patients will be enrolled at more than 300 sites

...

Related Keywords

California ,United States ,San Carlos ,Texas ,Canada ,America ,Matthew Galsky ,Androl Urol ,Clinical Laboratory Improvement Amendments ,National Cancer Institute ,Alliance For Clinical Trials In Oncology ,Nasdaq ,Community Research Oncology Program ,National Clinical Trials Network ,Kantar Health Cerner Enviza ,National Institutes Of Health ,Natera Inc ,Tisch Cancer Institute ,Clinical Trials ,National Institutes ,Bladder Cancer ,Tisch Cancer ,Minetta Liu ,Research Oncology Program ,Looking Statements ,Kantar Health ,Cerner Enviza ,Transl Androl ,Markets ,